Tomáš Páleníček

Tomáš Páleníček is a Czech clinical neuroscientist and psychopharmacologist whose work spans preclinical and human experimental studies of serotonergic psychedelics. He has contributed to both animal and human research programmes examining the neurophysiological and behavioural effects of compounds such as psilocin/psilocybin and 5‑MeO‑DMT. His research portfolio includes cross‑species investigations of perceptual distortions, EEG and event‑related potential studies (P300, mismatch negativity), and receptor‑binding correlates of lasting psychological change following single doses of psilocybin.

Páleníček has been involved in studies that link acute pharmacology to persistent changes in mindfulness, life satisfaction and reductions in psychopathological symptoms, and he has explored 5‑HT2A receptor dynamics as a mechanistic substrate of psilocybin's effects. He also investigates 5‑MeO‑DMT as a pharmacological model for altered or 'deconstructed' conscious states. His work is characterised by translational methods that integrate behavioural, electrophysiological and molecular/neuroimaging measures, and by collaborations within Czech and international psychiatric neuroscience groups focused on advancing the scientific basis for therapeutic applications of psychedelics.